The current standard-of-care for HER2-amplified/-overexpressed (HER2-positive) early breast cancer (EBC) is anti-HER2 therapy plus chemotherapy, irrespective of hormone receptor (HR) status/molecular features. Here, NR4A1 is linked to breast cancer.